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Methods: Fusion proteins consisting of nonallergenic peptides
from the 4 major timothy grass pollen allergens and the PreS
protein from hepatitis B virus as a carrier were expressed in
Escherichia coli and purified by means of chromatography.
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Rabbits were immunized with PreS fusion proteins to
characterize their immunogenicity.
Results: Ten hypoallergenic PreS fusion proteins were
constructed, expressed, and purified. According to
immunogenicity and induction of allergen-specific blocking IgG
antibodies, 4 hypoallergenic fusion proteins (BM321, BM322,
BM325, and BM326) representing Phl p 1, Phl p 2, Phl p 5, and
Phl p 6 were included as components in the vaccine termed
BM32. BM321, BM322, BM325, and BM326 showed almost
completely abolished allergenic activity and induced
significantly reduced T-cell proliferation and release of
proinflammatory cytokines in patients’ PBMCs compared
with grass pollen allergens. On immunization, they induced
allergen-specific IgG antibodies, which inhibited patients’ IgE
binding to all 4 major allergens of grass pollen, as well as
allergen-induced basophil activation.
Conclusion: A recombinant hypoallergenic grass pollen allergy
vaccine (BM32) consisting of 4 recombinant PreS-fused grass
pollen allergen peptides was developed for safe immunotherapy of
grass pollen allergy. (J Allergy Clin Immunol 2015;135:1207-17.)
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Because of their worldwide distribution and heavy pollen
production, grasses are among the most important allergen
sources.1,2 Grass pollen allergy affects almost 50% of patients,
with IgE-associated allergy and allergic rhinoconjunctivitis
(ie, hay fever) and asthma being the most frequent symptoms.3,4
Already in 1880, grass pollen was recognized as a potent
allergen source, and provocation tests were developed for diag-
nosis of grass pollen allergy.5 In 1911, the first allergen-specific
immunotherapy (SIT) trial was performed in patients with grass
pollen allergy.6 SIT is based on the administration of the
disease-eliciting allergens, with the goal to induce clinical
tolerance in patients.7 It is the only allergen-specific treatment
for allergic patients and, unlike pharmacotherapy, has disease-
modifying and long-lasting effects.8,9 However, side effects
caused by allergen administration limit the broad application of
SIT for allergy treatment.10 The most frequent and severe side
effects were found in SIT for grass pollen allergy when compared
with that for other allergens.11
At present, several alternative forms of SITare being developed
and subjected to clinical evaluation to improve the safety, efficacy,1207
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istration and molecular forms of treatment based on recombinant
allergens, hypoallergenic allergen derivatives, and allergen-
derived peptides.12-23
The spectrum of grass pollen allergens, in particular those from
timothy grass pollen, which contains the majority of the relevant
epitopes needed for grass pollen SIT,24 has been well defined.2 In
particular, those major timothy grass pollen allergens required as
essential components for grass pollen SIT have been identified by
using several serologic and clinical studies, and available data
suggest that a mix of recombinant group 1, 2, 5, and 6 allergens
is effective for treatment.25-29
Here we report the development and preclinical characteriza-
tion of a hypoallergenic grass pollen allergy vaccine, designated
BM32. The active components of the vaccine included
nonallergenic peptides derived from the major IgE-binding sites
of the 4major timothy grass pollen allergens Phl p 1, Phl p 2, Phl p
5, and Phl p 6, which were fused to the hepatitis B–derived PreS
domain and expressed in Escherichia coli in large amounts and
purified to homogeneity. In the fusion proteins the PreS domain
functions as a nonallergenic carrier protein, which provides
T-cell help for the induction of allergen-specific blocking
antibodies on immunization.
The reduction of allergenic and inflammatory activity of the
fusion proteins was investigated by using IgE reactivity and
basophil activation testing, as well as by studying T-cell
proliferation and cytokine release in allergic patients. Further-
more, the fusion proteins were formulated as a vaccine through
adsorption to aluminum hydroxide and, on immunization of
rabbits or treatment of sensitized mice, induced allergen-specific
IgG antibodies, which blocked IgE binding to the allergens and
allergen-specific basophil activation in allergic patients.METHODS
Allergic patients, timothy grass pollen extract,
recombinant allergens, synthetic peptides, and
antibodies
Information regarding materials and patients can be found in the Methods
section in this article’s Online Repository at www.jacionline.org.Expression and purification of hexahistidine-tagged
recombinant PreS fusion proteins and recombinant
PreS
Codon-optimized DNAs encoding fusion proteins consisting of allergen-
derived peptides fused to the N- and C-terminus of PreS and containing a
C-terminal hexahistidine tag were synthesized (GenScript, Piscataway, NJ)
and inserted into the NdeI/XhoI sites of plasmid pET-27b (Novagen,
Darmstadt, Germany). Recombinant PreS and PreS fusion proteins were
expressed in E coli strain BL21(DE3) (Stratagene, La Jolla, Calif). After in-
duction of protein expression by adding isopropyl-b-D-thiogalactopyranoside
to a final concentration of 0.7 mmol/L, cells were cultured for 3 hours at 378C
and then harvested by means of centrifugation at 3500 rpm for 10 minutes.
His-tagged PreS and PreS fusion proteins were then purified by means ofnickel affinity chromatography (see the Methods section in this article’s
Online Repository). Recombinant PreS fusion proteins without His-tags
were also expressed in E coli and purified to homogeneity (H. Huber,
unpublished data).Specificities and titers of specific rabbit antibodies
and inhibition of IgE binding to allergens by rabbit
antibodies in allergic patients
Reactivity and titers of rabbit antibodies specific for grass pollen allergens,
allergen-derived peptides, and PreS were determined by means of ELISA.30
Inhibition of the binding of allergic patients’ IgE to grass pollen allergens
by rabbit antibodies was determined by using an IgE competition ELISA.31Assessment of IgE reactivity
IgE reactivity to allergens, peptides, PreS, and PreS fusion proteins in
allergic patients was determined by using ELISA and/or IgE dot blotting with
a RAST-based technique.32Determination of allergenic activity by
measurement of allergen-induced upregulation of
CD203c on patients’ basophils
Heparinized blood samples obtained from patients with grass pollen allergy
(n 5 31) were incubated in triplicates with increasing concentrations of
antigens (0.001-1 mg/mL), buffer, or the anti-IgE mAb E-124-2-8 (1 mg/mL;
Immunotech, Marseille, France), and upregulation of CD203c expression was
determined, as previously described.33 The inhibition of allergen-induced
CD203c upregulation by specific IgG antibodies was studied, as previously
described.34Lymphocyte proliferation and cytokine responses
of PBMCs from patients with grass pollen allergy
PBMCs from patients with grass pollen allergy (n 5 50) were isolated by
means of Ficoll (Amersham Biosciences, Uppsala, Sweden) density
gradient centrifugation. Aliquots of 2 3 105 cells were resuspended in
200 mL of serum-free UltraCULTURE medium (BioWhittaker, Rockland,
Me) supplemented with 2 mmol/L L-glutamine (Sigma, St Louis, Mo),
50 mmol/L b-mercaptoethanol (Sigma), and 0.02 mg of gentamicin per
milliliter (Sigma) and stimulated with 3 concentrations (100 mg per well,
50 mg per well, and 25 mg per well) of timothy grass pollen extract from
Stallergenes (Antony, France), with 3 concentrations (ie, 1 mg per well,
0.5 mg per well, or 0.25 mg per well of each of the 4 BM32 fusion proteins)
of the BM32 fusion proteins, medium alone (negative control), or IL-2 (4 IE
per well, positive control). The concentration of themajor timothy grass pollen
allergen Phl p 5 in the timothy grass pollen extract was determined with a
quantitative sandwich ELISA30 to be 1 mg of Phl p 5 in 100 mg of total
proteins. After 6 days of culture, proliferative responses were measured based
on tritiated thymidine incorporation and were expressed as stimulation
indices.35 IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IL-13, IFN-g, TNF-a, and
GM-CSF levels were quantified in supernatants from PBMC cultures, which
were identically prepared as for the proliferation experiments by using the
Bio-Plex Human 17-Plex Panel (Bio-Rad Laboratories, Hercules, Calif),
xMAP Luminex fluorescent bead–based technology, and a Luminex 100
system for measurements (Luminex, Austin, Tex).35 Shown are results for
50 mg per well of timothy grass pollen extract and 0.5 mg per well of each
BM32 protein.Murine model of grass pollen allergy and basophil
activation testing in mice
Immunizations of mice with BM32 and measurement of T-cell and
antibody responses were performed, as described in the Methods section in
this article’s Online Repository. A murine model of grass pollen allergy was
FIG 1. Scheme for the preclinical development of a hypoallergenic grass
pollen allergy vaccine based on carrier-bound allergen peptides.
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allergen-induced basophil activation was measured, as described in the
Methods section in this article’s Online Repository.
Statistical analysis
For statistical analyses, GraphPad Prism 6 software (GraphPad Software,
La Jolla, Calif) was used. Differences between the groups regarding T-cell
reactivity are compared with the Wilcoxon signed rank test. Differences in
basophil activation in mice were calculated by using the unpaired t test.
P values of less than .05 were considered significant.
RESULTS
Molecular design of the grass pollen allergy vaccine
BM32 based on the peptide-carrier technology
The design of the vaccine components of BM32was carried out
according to the process summarized in Fig 1. The first step in
this process is the selection of the clinically relevant grass pollen
allergens to be included. Phl p 1, Phl p 2, Phl p 5, and
Phl p 625,26,36-39 have been identified previously as essential
vaccine components on the basis of IgE reactivity profiles of
patients with grass pollen allergy, IgE cross-reactivity with
natural grass pollen allergens, and assessments of allergenic
activities. A mix of these wild-type allergens was tested clinically
in an SIT study and was found to be efficacious.27
Protein design then began with identification of hypoallergenic
peptides derived from the major IgE-binding sites of these
allergens.22,23 Selection criteria were the absence of IgE binding,
reduced potential to activate allergen-specific T cells, and
induction of blocking antibody responses on immunization afterconjugation to KLH. Suitable peptides had been already
described for the 2 major allergens Phl p 1 and Phl p 5.31,35 In
the case of Phl p 1, a C-terminal peptide, P5-1, was identified,31,40
whereas for Phl p 5, a mixture of 4 peptides (ie, P1-5, P2-5, P5-5,
and P6-5) was found to be required to induce a sufficient blocking
IgG antibody response.35
For identification of hypoallergenic Phl p 2 and Phl p 6
peptides, 4 Phl p 2–derived peptides (P1-2 to P4-2) and 4 Phl p
6–derived peptides (P1-6 to P4-6) were synthesized and tested.
Three nonallergenic peptides (see Table E1 in this article’s
Online Repository at www.jacionline.org [P1-2, P3-2, and P4-
2]) had been identified for the construction of a hypoallergenic
Phl p 2 mosaic protein.41 In addition to these 3 peptides, another
peptide, P2-2, which, according to the nuclear magnetic
resonance and crystal structure of Phl p 2 (1CQA PDB accession
number),42,43 was rich in surface-exposed amino acids and which
also contained several amino acids from a conformational epitope
defined by an IgE Fab from an allergic patient on Phl p 243 was
synthesized. We tested the 4 Phl p 2–derived peptides for IgE
reactivity and found that none of them showed any relevant IgE
binding when compared with Phl p 2 (see Fig E1 in this article’s
Online Repository at www.jacionline.org).
The selection of peptides to be screened for IgE reactivity and
immunogenicity of Phl p 6 was driven by several considerations.
Phl p 6 consists of 4 anti-parallela-helices.39 A recombinant Phl p
6 fragment comprising amino acids 31 to 110, thus lacking the
N-terminal a-helix, was found to be hypoallergenic and to induce
a robust Phl p 6–specific IgG response, inhibiting IgE binding to
Phl p 6 in allergic patients.39 On the basis of this knowledge and
computer-aided prediction of surface-exposed areas of Phl p 6, we
synthesized 4 peptides (ie, P1-6 to P4-6; see Table E1), of which
each roughly corresponded to the 4 a-helices of rPhl p 6.39 Only
P2-6 showed IgE reactivity almost comparable with that of
complete Phl p 6 (see Fig E2 in this article’s Online Repository
at www.jacionline.org).
Next, we investigated which peptides induce allergen-specific
IgG responses on immunization. Fig E3 in this article’s Online
Repository at www.jacionline.org shows reactivities of
peptide-specific IgG antibodies with the corresponding aller-
gens. For each of the 2 allergens, one peptide (ie, Phl p 2: P4-
2; Phl p 6: P1-6) could be identified that induced levels of IgG
antibodies comparable to those induced by the complete allergen
(see Fig E3).
We then analyzed whether peptide-specific IgG antibodies
inhibit IgE binding to the allergen in allergic patients. We found
that anti–P4-2 (Phl p 2) and anti–P1-6 (Phl p 6) antibodies
produced a greater than 70%mean inhibition of IgE binding to the
corresponding allergens in allergic patients (see Tables E2 and E3
in this article’s Online Repository at www.jacionline.org).
Because these peptides also induced no relevant proliferation
and proinflammatory cytokine responses in PBMCs from patients
with grass pollen allergy (data not shown), they were selected as
components to be included in the grass pollen vaccine.
An important feature of the peptide-carrier technology is
that T-cell help for induction of allergen-specific IgG on immu-
nization is obtained by fusing the peptides to a nonallergenic
carrier molecule (Fig 1).22,23,44 The PreS coat protein derived
from hepatitis B virus was selected based on its immunogenicity
and safety in previous use as a hepatitis B vaccine and its high
expression yield in Escherichia coli.32,45,46 Ten different PreS
fusion proteins were designed by using peptides P5-1 of Phl p
FIG 2. Overview of recombinant fusion proteins consisting of PreS-fused
allergen peptidesmade for Phl p 1, Phl p 2, Phl p 5, and Phl p 6. Names of the
fusion proteins are shown at the right margin.
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of Phl p 6 as the allergen-specific moieties. They were expressed
in E coli, purified, and characterized. A schematic representation
of these fusion proteins is shown in Fig 2. For immunization ex-
periments, the fusion proteins were adsorbed to aluminum hy-
droxide, which is one of the most common adjuvants used in
SIT vaccines.
Construction, expression, and purification of
recombinant fusion proteins consisting of hepatitis
B–derived PreS and allergen-derived peptides
For Phl p 1, Phl p 2, and Phl p 6, for which a single peptide
was sufficient to induce allergen-specific blocking IgG, we
engineered fusion proteins containing either 1 or 2 copies of the
peptide fused to the N- and C-terminus of PreS, yielding fusion
proteins with 2 (ie, Phl p 1-A, Phl p 2-A, and Phl p 6-A) or 4
(ie, Phl p 1-B, Phl p 2-B, Phl p 6-B) peptide copies (Fig 2). In the
case of Phl p 5, 4 different peptides were required to induce
blocking IgG. Therefore we constructed proteins containing
P1-5 and P2-5 or P6-5 and P5-5 fused to the N-terminus, as
well as the C-terminus, of PreS (Phl p 5-A and Phl p 5-B). In
addition, 2 fusion proteins were made containing one copy of
each of the 4 peptides, one in which P1-5 and P2-5 were
added to the N-terminus and P6-5 and P5-5 were added to the
C-terminus (ie, Phl p 5-C) and a second in which P1-5 and P2-5
were at the C-terminus and P6-5 and P5-5 were at the N-terminus
(ie, Phl p 5-D; Fig 2).
The recombinant fusion proteins were expressed in E coli and
purified as soluble proteins with good yields under conditions of
laboratory scale expression (ie, 20-25 mg/L culture; see Fig E4
in this article’s Online Repository at www.jacionline.org).
Matrix-assisted laser desorption/ionization time-of-flight mass
spectrometry of the recombinant fusion proteins showed that
the molecular weights deduced from their sequences without
methionines were in agreement with the actual masses (data not
shown).Recombinant PreS fusion proteins show no IgE
reactivity and induce allergen-specific IgG
antibodies
The recombinant fusion proteins were compared regarding IgE
reactivity with the corresponding wild-type allergens in repre-
sentative numbers of allergic patients (Phl p 1, n 5 73; Phl p 2,
n5 43; Phl p 5, n5 55; and Phl p 6, n5 39; Fig 3). None of the
fusion proteins showed any detectable IgE reactivity, whereas
each of the sera reacted with the wild-type allergens (Fig 3). Re-
combinant PreS showed no IgE reactivity, and sera from nonal-
lergic subjects did not exhibit IgE reactivity with any of the
proteins (Fig 3). The presence of the fusion proteins on the mem-
branewas confirmed by testing with PreS and peptide-specific an-
tibodies (data not shown).
To study the ability of the fusion proteins to induce blocking
IgG antibodies against wild-type allergens on immunization,
fusion proteins and, for comparison, complete allergens were
adsorbed to complete Freund adjuvant (CFA) and incomplete
Freund adjuvant or to aluminum hydroxide for immunization of
rabbits.
The testing of different dilutions of the rabbit antisera for IgG
reactivity to the wild-type allergens indicated that the fusion
proteins containing 4 copies of the allergen-derived peptides
induced higher titers of allergen-specific antibodies than
fusion proteins containing only 2 peptide copies (see Fig E5
in this article’s Online Repository at www.jacionline.org).
Interestingly, Phl p 5-D, which contained P6-5-P5-5 at the
N-terminus, induced higher Phl p 5–specific IgG levels than the
fusion protein containing P6-5-P5-5 at the C-terminus (ie, Phl p
5-C; see Fig E5). The Phl p 5–specific IgG titers induced with
Phl p 5-A or Phl p 5-B were not higher than those induced with
Phl p 5-D (data not shown), which was then selected as a vaccine
component because it combined all 4 Phl p 5 peptides in a single
protein.
Allergen-specific IgG antibodies induced by
immunization with peptides and PreS fusion
proteins inhibit allergic patients’ IgE binding to
grass pollen allergens
Next, we analyzed whether rabbit antibodies induced by
immunization with the various PreS fusion proteins can inhibit
allergic patients’ IgE binding to allergens. The relative inhibition
(as a percentage) of IgE binding obtained with antibodies from
rabbits immunized with different adjuvants and antigens are
shown for each of the 4 grass pollen allergens in Table I. Inhibi-
tion experiments were performed with sera from patients with
grass pollen allergy whowere sensitized against the individual al-
lergens (Phl p 1, n5 19; Phl p 2, n5 19; Phl p 5, n5 16; and Phl p
6, n 5 21). For each wild-type allergen and PreS fusion protein,
rabbits immunized with CFA and aluminum hydroxide (Table I,
CFA and Alu I) as an adjuvant are displayed. Furthermore, one
rabbit was immunized with the KLH-coupled peptides in CFA
for comparison.
Overall, we found that the mean degree of inhibition of IgE
binding was in a similar range for antibodies raised with the
complete allergens, PreS fusion proteins, or KLH-coupled
peptides (Table I).
The comparison of the percentage of inhibition of IgE binding
obtained with anti–Phl p 6-A and anti–Phl p 6-B antibodies
indicated that the blocking antibody responses induced by Phl p
FIG 3. Comparison of the IgE reactivity of recombinant grass pollen allergens, fusion proteins, and PreS. IgE
reactivity of sera from patients with grass pollen allergy and from a nonallergic person (N) to dot blots of
rPhl p 1, Phl p 1-A, Phl p 1-B, and PreS (A); rPhl p 2, Phl p 2-A, Phl p 2-B, and PreS (B); rPhl p 5, Phl p 5-A,
Phl p 5-B, Phl p 5-C, Phl p 5-D, and PreS (C); and rPhl p 6, Phl p 6-A, Phl p 6-B, and PreS (D) are shown.
TABLE I. Percentages of inhibition of allergic patients’ IgE binding to allergens with specific rabbit IgG antibodies
Allergen CFA Alu I CFA Alu I CFA Alu I CFA No. of sera
Phl p 1
Immunogen Phl p 1 Phl p 1-A Phl p 1-B Peptide-KLH
Mean 95.1 93.0 42.2 88.7 91.7 68.7 94.3 n 5 19
Range 90.3-97.9 89.6-96.6 10.7-66.6 75-93.2 77.9-96.5 36.2-76.5 81.7-97.8
Phl p 2
Immunogen Phl p 2 Phl p 2-A Phl p 2-B Peptide-KLH
Mean 87.8 89.5 94.0 91.4 89.0 91.0 83.2 n 5 19
Range 62.4-95 61.8-96.7 89.0-97.3 86.3-95.8 77.9-90.02 80.2-94.1 54.5-91.3
Phl p 5
Immunogen Phl p 5 Phl p 5-C Phl p 5-D Peptide-KLH
Mean 97.0 95.3 73.8 82.4 82.3 92.1 79.3 n 5 16
Range 90.9-99.5 89.7-97.3 54.2-89.7 76.8-92 71.9-92.5 84.1-96.7 60.9-92.9
Phl p 6
Immunogen Phl p 6 Phl p 6-A Phl p 6-B Peptide-KLH
Mean 81.4 46.5 84.1 46.0 83.4 67.0 82.8 n 5 21
Range 78-99 24.9-87.2 17.2-96.3 21.8-78.2 49.1-96.5 20.2-75.7 44.9-97.4
Alu I, Aluminum hydroxide.
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Phl p 6-A containing only 2 peptide copies. Interestingly, the
blocking antibody responses induced with the Phl p 5-D
fusion protein were slightly better than those induced with the
Phl p 5-C fusion protein, although only the order of the peptides in
the constructs was different (Table I). Blocking antibodyresponses induced with the Phl p 1 and Phl p 2 variants were
comparable regardless of the number of peptide copies in the
constructs. However, one rabbit immunized with aluminum
hydroxide–adsorbed Phl p 2-A containing only 2 peptide copies
did not mount Phl p 2–specific IgG responses (see Fig E5).
Regarding the Phl p 1 derivatives, we observed that Phl p 1-A
AB
FIG 4. Comparison of the allergenic activity of an equimolar mix of recombinant grass pollen allergens (Phl
p 1, 2, 5, and 6) with PreS and an equimolar mix of recombinant BM proteins (BM321-6). Basophils from
patients with grass pollen allergy (n 5 31; A: S1-S16; B: S17-S31) were exposed to different concentrations
of the proteins (x-axes; white bars, BM mix; dark gray bars, allergen mix; light gray bars, PreS), anti-IgE, or
buffer (controls; black bars). Allergen-induced upregulation of CD203c was calculated from mean
fluorescence intensities (MFIs) obtained with stimulated (MFIstim) and unstimulated (MFIcontrol) cells and
is expressed as the stimulation index (MFIstim: MFIcontrol; means 6 SDs of triplicates; y-axes).
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FIG 5. Comparison of a mix of recombinant BM proteins with natural grass pollen extract regarding the
induction of proliferation and cytokine production in PBMCs of patients with grass pollen allergy.
Lymphocyte proliferation responses (stimulation indices [SI]) and cytokine levels (in picograms per
milliliter; y-axes) are displayed for cultured PBMCs from 50 patients with grass pollen allergy after exposure
to the mix of BM proteins (left, open circles, 0.5 mg per well of each BM32 protein) or grass pollen extract
(right, open diamonds, 50 mg per well of total proteins). Significant differences between the mix of BM
proteins and grass pollen are indicated. ns, Not significant. *P < .05 and **P < .0001.
J ALLERGY CLIN IMMUNOL
VOLUME 135, NUMBER 5
FOCKE-TEJKL ET AL 1213adsorbed to CFA induced less blocking IgG than CFA-adsorbed
Phl p 1-B.
Selection of the final components of the grass
pollen allergy vaccine BM32
Because none of the tested derivatives showed allergen-specific
IgE reactivity, the best inducers of blocking IgG (ie, Phl p 6-B, Phl p
5-D, Phl p 2-B, and Phl p 1-B) were selected as components for the
final vaccine. They obtained the following designations: Phl p 1-B,
BM321; Phl p 2-B, BM322; Phl p 5-D, BM325; and Phl p 6-B,
BM326. These components were manufactured at the scale ofseveral hundred milligrams without a His-tag and by using a Good
Manufacturing Practice compatible process (Huber, unpublished).
The resulting material was applied for further evaluation of the
allergenic activity, T-cell reactivity, and induction of proinflamma-
tory cytokines.
Mixture of recombinant BM321, BM322, BM325,
and BM326 shows almost completely abolished
allergenic activity
By using blood samples from 31 patients with grass pollen
allergy, which had been collected at the grass pollen peak season of
FIG 6. Inhibition of allergen-induced upregulation of CD203c on basophils of patients with grass pollen allergy
by anti-BM32 IgG antibodies. Shown are representative results for basophils from 2 patients (upper and lower
panels) with grass pollen allergy. Patients’ PBMCs were incubated with different concentrations of the mix of
recombinant grass pollen allergens that had been preincubated with rabbit anti-BM32 IgG antibodies (gray
bars) or IgG from rabbits before immunization (Pre IgG: white bars), with anti-IgE or buffer alone (black
bars; x-axes). Upregulations of CD203c expression are shown as mean stimulation indices 6 SD (y-axes).
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BM32 mix) was compared with that of an equimolar mix of the
correspondingwild-type allergens (Phl p 1, Phl p 2, Phl p 5, and Phl
p 6; Fig 4). Although basophils of 23 of the 31 the patients showed
full upregulation of CD203c expression already at the lowest wild-
type allergen concentration tested (ie, 0.001mg/mL), theBM32mix
did not induce any relevant upregulation of CD203c expression in
basophils from 29 of the 31 patients, even at the highest concentra-
tion tested (ie, 1 mg/mL; Fig 4). Only in 2 patients (ie, S7 and S24)
was a residual allergenic activity of the BM32 mix found (Fig 4).The BM32mix induces lower T-cell proliferation and
production of proinflammatory cytokines in
cultured PBMCs from patients with grass pollen
allergy than grass pollen allergens
PBMCs from 50 patients with grass pollen allergy were exposed
to the BM32 proteinmix and natural timothy grass pollen allergens(Fig 5).We found that the BM32mix induced a significantly lower
T-cell proliferation compared with natural grass pollen allergens.
There was no significant difference regarding the secretion of IL-
2 in the cultures of BM32- or grass pollen allergen–stimulated
PBMC cultures. However, the BM32 mix induced a significantly
lower production of proinflammatory cytokines (ie, granulocyte
colony-stimulating factor, GM-CSF, TNF-a, IL-1b, IL-6, IL-17,
IL-7, IL-12, IFN-g, IL-4, IL-5, and IL-13; Fig 5).IgG antibodies induced by means of immunization
with the BM32 grass pollen vaccine inhibit allergen-
induced basophil activation in patients and mice
We also immunized rabbits with an aluminum hydroxide–
adsorbed mix containing 40 mg of each BM32 protein and
investigated whether anti-BM32 IgG antibodies can inhibit grass
pollen allergen–induced basophil activation in patients with grass
pollen allergy. As exemplified for 2 patients in Fig 6, we found
FIG 7. A, Scheme of treatment with BM32 in amurinemodel of grass pollen allergy. Mice were sensitized by
means of subcutaneous (s.c.) injection and bymeans of intranasal challenge with recombinant grass pollen
allergens split into 2 groups, one of which was treated with BM32 and the other with PBS alone. Allergen-
induced basophil activation testing was done on day 188. B, Basophils from grass pollen–sensitized mice
treated with BM32 (n 5 6) or PBS (n 5 6, x-axis) were stimulated with either Phl p 1, Phl p 5, or Phl p 6
(top line). Shown are the mean fluorescence intensities (MFIs; y-axis) of CD200R expression for the mice
in each group. Medians are indicated as horizontal bars for each group, and significant differences between
the BM32 and PBS groups are indicated. *P < .05. The horizontal line indicates mean baseline expression of
CD200R expression for the medium controls.
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more than 100-fold inhibition of allergen-induced basophil
activation compared with incubation with the corresponding
preimmune antibodies.
Similar results were obtained in an in vivo model of grass
pollen allergy (Fig 7, A). Treatment with BM32 reduced
allergen-induced basophil activation in sensitized mice
significantly for Phl p 1 and Phl p 6 (P < .05) when compared
with that seen in PBS-treated mice. A reduction of basophil
activation was noted also for Phl p 5 stimulation (Fig 7, B).DISCUSSION
In this study we have used the peptide-carrier technology22,23
to develop a hypoallergenic vaccine for SIT of grass pollen al-
lergy. Grass pollen is one of the most potent and frequent elicitors
of respiratory allergies treated with SIT. However, SITwith natu-
ral grass pollen allergens induces frequently severe side effects.11
With the goal to produce a safe vaccine, we have used non-
allergenic peptides from the IgE-binding sites of the 4 major
timothy grass pollen allergens Phl p 1, Phl p 2, Phl p 5, and Phl
p 6 for construction of the vaccine. The 4 timothy grass pollen
allergens were selected as templates because extensive IgE
reactivity and IgE cross-reactivity studies, as well as clinical
studies, indicated that they are the clinically most relevant
allergens in patients with grass pollen allergy.29 The allergen-
derived but nonallergenic peptides are fused to a carrier protein
to obtain fusion proteins that, upon immunization, induce
allergen-specific IgG antibodies that are focused to the major
IgE-binding sites on the allergens. The induced allergen-
specific IgG antibodies hence are expected to block patients’
IgE binding to the allergen and the subsequent allergic immuneresponses caused by the formation of IgE-allergen immune
complexes (eg, allergen-induced mast cell and basophil
activation, IgE-facilitated allergen presentation, and allergen-
induced boosts of IgE production).7
We were able to identify nonallergenic peptides from the
IgE-binding epitopes of the 4 major timothy grass pollen
allergens Phl p 1, Phl p 2, Phl p 5, and Phl p 6. By means of
their incorporation into fusion proteins with PreS, we were able
to obtain vaccine candidates that were easy to manufacture in
large amounts. We have already described hypoallergenic fusion
proteins for cat and birch pollen allergy using PreS as a
carrier,32,45 which were obtained through a similar design
process. The immunologic characterization of the BM32 fusion
proteins showed that they had almost completely lost their
allergenic activity, as demonstrated in extensive IgE-binding
and basophil activation experiments. Furthermore, the BM32
fusion proteins showed significantly reduced ability to induce
the proliferation of allergen-specific T cells and the release of
proinflammatory cytokines when compared with grass pollen
allergens in cultured PBMCs from allergic patients. The
strongly reduced allergenic activity of the BM32 proteins opens
the possibility to safely administrate high doses of the BM32
mix to allergic patients with only a few injections, which would
offer significant practical advantages for their clinical use as
vaccines. This assumption was supported by immunization
experiments showing that the BM32 proteins induced high
levels of allergen-specific IgG antibodies on immunization of
rabbits. The analysis of antibody and T-cell responses in
BM32-immunized mice showed that T-cell help for the
production of IgG antibodies comes mainly from carrier
(ie, PreS)–specific T cells (see Fig E6 in this article’s Online
Repository at www.jacionline.org).
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inhibited allergic patients’ IgE binding to the wild-type allergens
to a similar degree as IgG antibodies induced by immunization
with wild-type allergens. Furthermore, BM32-induced IgG
inhibited allergen-specific basophil activation, suggesting that a
BM32-based vaccine will induce allergen-specific IgG, which
protects patients against immediate allergic inflammation, the
most frequent and common cause of allergic symptoms in patients
with grass pollen allergy. The therapeutic effect of the BM32
vaccine could also be shown in an experimental animal model of
grass pollen allergy in which treatment with BM32 reduced
allergen-induced basophil activation in sensitized mice. Studies
performed with natural allergen extract–based vaccines, CpG-
conjugated allergens, and vaccines based on recombinant aller-
gens and hypoallergens have shown that allergen-specific IgG
also prevents boosts of allergen-specific IgE production and
allergen-specific T-cell activation.47-51 Thus it is tempting to
speculate that vaccination with BM32 will have similar beneficial
effects and will also reduce allergen-specific T-cell responses and
IgE production in addition to blocking allergen-induced mast cell
and basophil activation. First experiences obtained with BM32 in
clinical trials (skin test study: NCT01350635; safety and dose-
finding study, phase IIa: NCT01445002; multicenter, double-
blind, placebo-controlled efficacy study, phase IIb:
NCT01538979) suggest that BM32 will bring us closer to an
effective, safe, and convenient grass pollen allergy vaccine, which
might be beneficial for a large number of allergic patients.
We thank Karin Fleischmann and Vera Civaj from the Christian Doppler
Laboratory of Allergy Research, Department of Pathophysiology and Allergy
Research, Medical University of Vienna, for technical assistance.
Clinical implications: The recombinant hypoallergenic allergy
vaccine BM32 reported in our study should allow safe and
effective immunotherapy of grass pollen allergy.REFERENCES
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METHODS
Allergic patients’ sera and blood samples, timothy
grass pollen extract, recombinant allergens,
synthetic peptides, and antibodies
Patients with grass pollen allergy, as well as nonallergic control subjects,
were characterized by case history and results of skin prick testing and
measurement of specific IgE antibodies to recombinant grass pollen allergens
(rPhl p 1, rPhl p 2, rPhl p 5, and rPhl p 6), as previously described.E1
Anonymized residual serum samples from these patients and from subjects
without grass pollen allergy were used for serologic experiments with
approval of the ethics committee of the Medical University of Vienna.
Heparinized blood samples for T-cell proliferation and CD203c assays
were obtained from patients with grass pollen allergy (NCT01350635) after
informed consent was provided.
Recombinant grass pollen allergens were provided by Biomay AG.
Timothy grass pollen extract was obtained from Stallergenes. Phl p 2 and
Phl p 6 peptides were synthesized and purified, as previously described.E2
Rabbit antibodies specific for allergens (Phl p 1, Phl p 2, Phl p 5, and
Phl p 6) or allergen-derived peptides were obtained by immunizing rabbits
with purified recombinant proteins or with the KLH-coupled peptides
(Charles River, Kissleg, Germany) 3 times in monthly intervals with 200 mg
of antigen emulsified once in CFA and twice in Freund incomplete adjuvant.
Antibodies specific for PreS fusion proteins were raised by using the same
CFA protocol and additionally by immunizing with aluminum hydroxide–
adsorbed proteins (100 mg per injection for single fusion proteins or
with the BM32 vaccine containing 40 mg of each of the 4 fusion proteins).
PreS-specific rabbit antibodies are described by Niespodziana et al.E3
Purification of His-tagged recombinant PreS and
peptide-carrier fusion proteins
For Phl p 1-A and Phl p 1-B, Phl p 6-A and Phl p 6-B, or Phl p 5-A, Phl p 5-B,
and Phl p 5-D, the bacterial cell pellets obtained from induced liquid cultures
were thawed for 15 minutes on ice and resuspended under native conditions in
lysis buffer I (50 mmol/L NaH2PO4 and 200 mmol/L NaCl containing
10 mmol/L imidazole, pH 7.5). After incubation with lysozyme (1 mg/mL,
Sigma-Aldrich) for 30 minutes on ice, cells were lysed by means of repetitive
freezing and thawing, and DNAse I (5mg/mL)was added. For PreS, Phl p 2-A,
Phl p 2-B, and Phl p 5-C cell pellets were thawed for 15 minutes on ice and
solubilized in Buffer II (100 mmol/L NaH2PO4 and 10 mmol/L Tris-HCl,
pH 8.0, containing 6 mol/L Gu HCl for PreS or 8 mol/L urea for Phl p 2-A,
Phl p 2-B, and Phl p 5-C) by stirring for 1 hour at room temperature.
In both protocols the lysates were cleared by means of centrifugation
(14,000 rpm for 20 minutes at 48C), and recombinant fusion proteins were
purified by using nickel affinity chromatography (Qiagen, Hilden, Germany).
For proteins from inclusion bodies, elution was done with buffer II containing
8 mol/L urea (pH 3.5). Urea was removed by using dialysis either against 10
mmol/LTris (pH 7.5) for PreS fusion proteins or against 10 mmol/L NaH2PO4
(pH 4.8) for PreS. For purification under native conditions, an elution buffer
containing 10 mmol/L Tris, 200 nmol/L NaCl, and 250 mmol/L imidazole
was used, followed by ultrafiltration (Amicon Ultra 15; Merck KGaA,
Darmstadt, Germany) for concentration of samples. The purity of recombinant
proteins was analyzed by using SDS-PAGE and Coomassie staining. Protein
concentrations were determined by measuring protein-specific ODs as
280 nmE4 and by using a BCA Protein Assay Kit (Novagen, Madison, Wis).
The identity of the fusion proteins was confirmed by means of immunoblot-
tingwith rabbit anti-peptide anti-sera (Phl p 1: rabbit anti-P5; Phl p 2: rabbit anti-
P4; Phl p 6: rabbit anti-P1; Phl p 5: rabbit anti-P1, anti-P2, anti-P5, and anti-P6)
and anti-PreS antibodies diluted 1:2500.E3 Bound rabbit antibodies were
detected with iodine 125–labeled goat anti-rabbit IgG (PerkinElmer, Waltham,
Mass) diluted 1:2500 for 1 hour and visualized by means of autoradiography.E5
Mouse immunization, antibody, and T-cell
proliferation responses
Six-week-old female BALB/c mice (Charles River, Sulzfeld, Germany)
were used in the study. The animals were maintained in the Animal Care
Unit of the Department of Pathophysiology and Allergy Research (Medical
University of Vienna), according to local guidelines for animal care. Six mice
were immunized subcutaneously 3 times with BM32, containing 10 mg of
each BM32 component adsorbed to aluminum hydroxide (SERVA
Electrophoresis, Heidelberg, Germany) in 4-week intervals and once after
16 weeks. Blood samples were drawn from the tail vein before immunization
at weeks 4, 8, 12, 16, and 22. Lymphoproliferative responses in mice were
measured in spleen cell cultures at week 22 stimulated with PreS (0.06 mg per
well) and timothy grass pollen extract (10 mg per well, Stallergenes),
concanavalin A (0.5 mg per well, positive control), or medium alone,
as previously described.E6 PreS and grass pollen allergen extract–specific
IgG1 responses were measured by using ELISA.
E6 Results from T-cell
experiments and IgG1 measurements are shown as medians 6 SDs for the
group of 6 mice.
Mouse model for grass pollen allergy, treatment
with BM32, and basophil activation testing
Female BALB/cmice aged 6 to 8weeks (Charles River) weremaintained at
the animal facility of the University of Salzburg, according to local guidelines.
Mice (n 5 12) were sensitized on days 0 and 10 by means of subcutaneous
injection with a mixture of Phl p 1 (5 mg), Phl p 5 (1 mg), and Phl p 6 (5 mg)
adsorbed to aluminum hydroxide (Alu-Gel, SERVA). On days 24, 25, 26, 31,
32, and 33, mice were boosted by means of intranasal application of a mixture
containing 5mg of Phl p 1, 1mg of Phl p 5, and 5mg of Phl p 6 in 40mL of PBS.
Phl p 2 was not included because of its poor allergenicity and immunogenicity
in mice.E7 One group of mice (n5 6) was treated on days 48, 62, 76, 111, and
146 by means of subcutaneous injection of 200 mL of alum-adsorbed BM32
(containing 20 mg of each component), whereas the control group (n 5 6)
was sham treated by means of subcutaneous injection of 200 mL of PBS.
The basophil activation test was done at day 188. For this purpose, heparinized
blood samples from mice were diluted in RPMI and incubated with allergens
(30 mL of blood was diluted with 30 mL of RPMI 1640 [PAA, Pasching,
Austria] containing 200 mg/mL heparin and 100 ng/mL Phl p 1, 4 ng/mL
Phl p 5, or 4 ng/mL Phl p 6) for 2 hours at 378C and 7% CO2 in 96-well
V-bottom plates in duplicates (Greiner, Kremsm€unster, Austria). Cells were
washed with PBS, 1% wt/vol BSA, and 2 mmol/L EDTA and centrifuged at
500g for 5 minutes before surface staining with fluorescein isothiocyanate
anti-mouse IgE (RME-1; BioLegend, San Diego, Calif), peridinin-
chlorophyll-protein complex/Cy5.5 anti-mouse CD4 (GK1.5, BioLegend),
phycoerythrin/Cy7 anti-mouse CD19 (6D5, BioLegend), and anti-CD200R
(OX110; eBioscience, San Diego, Calif), all diluted 1:200 in PBS, 1% wt/vol
BSA, and 2 mmol/L EDTA. After incubation, cells were washed twice with
PBS, 1% wt/vol BSA, and 2 mmol/L EDTA, followed by erythrocyte
lysis through resuspending the pellet in 100 mL of FACS Lysing Solution
(Becton Dickinson, San Jose, Calif). After a final wash, cells were analyzed
on a FACSCanto II flow cytometer (Becton Dickinson). T cells (CD41) and
B cells (CD191) were gated out, and basophils were gated as IgE1 and
CD200R1 cells.E8 Mean fluorescence intensities with an error of less than
10% are shown.
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FIG E1. Comparison of IgE reactivity to rPhl p 2 and Phl p 2–derived
peptides in patients. Displayed are IgE levels (y-axis: OD values; horizontal
bars 5 medians) specific for Phl p 2 or Phl p 2–derived peptides (P1-2 to
P4-2; x-axis) measured by means of ELISA in sera from patients with grass
pollen allergy (n 5 22).
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FIG E2. Comparison of IgE reactivity to rPhl p 6 and Phl p 6–derived
peptides in patients. Displayed are IgE levels (y-axis: OD values; horizontal
bars 5 medians) specific for Phl p 6 or Phl p 6–derived peptides (P1-6 to
P4-6; x-axis) measured by means of ELISA in sera from patients with grass
pollen allergy (n 5 22).
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AB
FIG E3. IgG reactivity of sera frompeptide-immunized rabbits with Phl p 2 (A)
and Phl p 6 (B). IgG reactivities (mean6 SDOD levels of triplicates; y-axes) to
Phl p 2 (Fig E3, A) or Phl p 6 (Fig E3, B) determined for different dilutions (x-
axes) of sera from rabbits immunized with the complete allergens or
KLH-coupled allergen-derived peptides are shown (Fig E3, A: Phl p 2 and
Phl p 2 peptides P1-P4; Fig E3, B: Phl p 6 and Phl p 6 peptides P1-P4).
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FIG E4. Coomassie-stained SDS-PAGE. Lanes contain purified fusion
proteins or markers (lanes M). Molecular weights (in kilodaltons) are
indicated on the left margin.
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FIG E5. Allergen-specific IgG reactivity of rabbits immunizedwith aluminum hydroxide–adsorbed allergens
or fusion proteins. IgG reactivities (y-axes, mean OD levels of triplicates) of rabbits immunized with the
complete recombinant allergens or the fusion proteins to Phl p 1 (A), Phl p 2 (B), Phl p 5 (C), or Phl p 6
(D) determined for different serum dilutions (x-axes) are shown. For each protein, 2 different rabbits were
immunized (I and II).
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BA
FIG E6. Lymphocyte proliferation and IgG1 responses in BM32-immunized
mice. Shown are lymphocyte proliferation responses at week 22
(stimulation indices [SI] as box plots: y-axis; whiskers 5 minimum and
maximum; horizontal bars 5 medians, boxes 5 25th to 75th percentiles)
to PreS and grass pollen allergen extract (x-axis) (A) and IgG1 reactivities
in preimmune sera (pre) and immune sera (IS: week 22; median 6 SD OD
levels, y-axis) measured for 6 BM32-immunized mice (B).
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TABLE E1. Characteristics of amino acids and molecular weights of synthetic allergen peptides
Allergen Accession no.
Amino acid
position Sequence
No. of
amino acids Weight (Da)
Phl p 1 P43213
P5-1 212-241 CVRYTTEGGTKTEAEDVIPEGWKADTSYESK 31 3452
Phl p 2 P43214
P1-2 1-33 VPKVTFTVEKGSNEKHLAVLVKYEGDTMAEVELC 34 3765
P2-2 8-39 VEKGSNEKHLAVLVKYEGDTMAEVELREHGSDC 33 3674
P3-2 34-64 REHGSDEWVAMTKGEGGVWTFDSEEPLQGPFNC 33 3697
P4-2 66-96 CFRFLTEKGMKNVFDDVVPEKYTIGATYAPEE 32 3699
Phl p 5 Q40960
P1-5 26-58 ADLGYGPATPAAPAAGYTPATPAAPAEAAPAGKC 34 3068
P2-5 59-92 CATTEEQKLIEKINAGFKAALAAAAGVQPADKYR 34 3578
P5-5 176-212 CAEEVKVIPAGELQVIEKVDAAFKVAATAANAAPANDK 38 3853
P6-5 217-246 CEAAFNDAIKASTGGAYESYKFIPALEAAVK 31 3236
Phl p 6 Y16956.1
P1-6 23-54 GKATTEEQKLIEDVNASFRAAMATTANVPPADC 34 3451
P2-6 56-90 CYKTFEAAFTVSSKRNLADAVSKAPQLVPKLDEVYN 36 4005
P3-6 73-104 CDAVSKAPQLVPKLDEVYNAAYNAADHAAPEDKY 34 3678
P4-6 95-127 CAADHAAPEDKYEAFVLHFSEALRIIAGTPEVHA 34 3661
For each allergen (Phl p 1, Phl p 2, Phl p 5, and Phl p 6), peptides of different locations and lengths were synthesized. Displayed are the names of allergens and peptides, database
accession numbers of allergens, positions of peptides in the allergens, sequences (cysteines added to facilitate coupling are shown in boldface and underlined), numbers of amino
acids, and molecular weights (in daltons).
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TABLE E2. Inhibition of allergic patients’ IgE binding to Phl p 2
with IgG specific for rPhl p 2 or for Phl p 2 peptides (P1-2 to P4-2)
Patient no. OD rPhl p 2 (%) P1-2 (%) P2-2 (%) P3-2 (%) P4-2 (%)
1 0.877 8.37 3.26 48.41 60.93 75.97
2 0.986 12.15 5.89 51.18 72.33 72.71
3 1.470 5.99 0.17 25.29 49.55 56.66
4 1.492 10.90 0.00 41.21 55.30 65.27
5 0.826 10.53 0.00 34.95 49.53 66.43
6 1.048 13.58 2.78 50.48 50.11 70.14
7 1.290 0.41 0.00 44.73 51.72 68.80
8 1.095 5.30 0.00 32.98 49.05 65.08
9 0.960 5.86 5.08 28.71 37.66 57.55
10 0.902 0.00 1.06 18.89 25.46 44.39
11 0.597 5.80 2.54 39.59 43.23 68.33
12 0.715 12.11 1.31 25.68 34.67 65.95
13 1.380 14.23 3.97 56.51 68.18 83.39
14 0.647 33.16 0.00 87.63 88.93 92.59
15 0.683 18.44 2.19 71.95 75.27 87.91
16 1.542 8.32 1.63 68.80 76.19 89.21
17 0.527 12.07 2.43 68.54 71.99 91.60
18 0.651 19.06 2.84 78.57 78.59 91.10
19 1.567 5.96 3.72 26.27 25.31 71.06
20 1.027 21.09 10.55 42.94 42.10 76.76
21 1.155 7.66 0.00 25.32 30.12 80.23
Mean 1.02 11.00 2.35 46.13 54.11 73.39
Displayed are Phl p 2–specific IgE levels (OD levels: first column, noninhibited) for
21 patients and the percentages of inhibition of IgE binding after preincubation with
allergen- or peptide-specific IgG. Mean values are shown in the bottom line.
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TABLE E3. Inhibition of allergic patients’ IgE binding to Phl p 6
with IgG specific for rPhl p 6 or for Phl p 6 peptides (P1-6 to P4-6)
Patient no. OD rPhl p 6 (%) P1-6 (%) P2-6 (%) P3-6 (%) P4-6 (%)
1 0.304 80.14 81.69 73.38 10.17 63.26
2 0.650 92.92 86.14 91.53 1.36 41.12
3 0.455 85.95 88.58 87.37 27.43 59.84
4 0.450 67.74 66.10 63.30 25.99 36.67
5 0.332 74.02 61.99 53.38 18.54 27.29
6 0.719 70.61 73.46 65.03 13.00 53.39
7 0.279 75.96 76.78 67.51 36.49 67.96
8 0.276 41.22 34.88 7.99 31.30 19.01
9 1.669 93.29 88.16 86.06 44.83 71.19
10 1.913 85.96 80.94 85.75 0.00 21.04
11 0.258 66.75 47.34 57.04 12.25 22.89
12 0.123 45.17 61.05 29.00 27.42 43.47
13 0.275 40.27 47.92 43.45 0.00 30.86
14 0.110 94.34 93.55 93.01 27.34 67.21
15 2.014 83.13 68.82 73.71 35.92 61.12
Mean 0.65 73.17 70.50 65.17 20.80 45.75
Displayed are Phl p 6–specific IgE levels (OD levels: first column, noninhibited) for
15 patients and percentages of inhibition of IgE binding after preincubation with
allergen- or peptide-specific IgG. Mean values are shown in the bottom line.
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